Literature DB >> 19509511

In vivo quantification of 18f-fdg uptake in human placenta during early pregnancy.

Paolo Zanotti-Fregonara1, Sebastien Jan, Christophe Champion, Régine Trébossen, Renaud Maroy, Jean-Yves Devaux, Elif Hindié.   

Abstract

18F-FDG is the most widely used PET radiopharmaceutical. Nevertheless, no data for 18F-FDG uptake in the human placenta have been reported. We recently reported on embryo dosimetry in a woman who underwent an 18F-FDG PET/CT scan during early pregnancy. In the present work we attempt an in vivo quantification of the 18F-FDG uptake by the placenta. The 27-y-old woman received 320 MBq of 18F-FDG for a follow-up study for Hodgkin's lymphoma and was later discovered to be pregnant (embryo age = 8 wk). Imaging started 1 h after injection. The maximum placental tissue uptake (SUVmax) was 2.5. This value was conservatively attributed to the entire placental volume, i.e., 45 mL, a value representative of the average dimensions of a normal placenta at 8 wk. On the basis of these measurements, placenta 18F-FDG uptake in our patient was 0.19% of the injected activity. A Monte Carlo simulation was used to derive the photon dose to the embryo from the placenta (0.022 x 10(-2) mGy per MBq of injected 18F-FDG) and from the surrounding amniotic fluid (0.017 x 10(-2) mGy MBq(-1)). This increases our previously calculated dose (3.3 x 10(-2) mGy MBq(-1)) by only a small fraction (1.18%), which does not justify modifying the previous estimate given the overall uncertainties.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509511     DOI: 10.1097/01.HP.0000346703.78971.0d

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  7 in total

1.  Radiation dose to the fetus from [(18)F]-FDG administration during the second trimester of pregnancy.

Authors:  Paolo Zanotti-Fregonara; Thomas M Koroscil; Joseph Mantil; Martin Satter
Journal:  Health Phys       Date:  2012-02       Impact factor: 1.316

2.  Development of computational pregnant female and fetus models and assessment of radiation dose from positron-emitting tracers.

Authors:  Tianwu Xie; Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-28       Impact factor: 9.236

3.  The use of PET/CT in pregnancy: A case report of malignant parathyroid carcinoma and a review of the literature.

Authors:  Manpreet Mona Gill; Winnie Sia; Michael Hoskinson; Erin Niven; Rshmi Khurana
Journal:  Obstet Med       Date:  2017-10-09

4.  PET/CT imaging reveals unrivaled placental avidity for glucose compared to other tissues.

Authors:  A B Sawatzke; A W Norris; F Spyropoulos; S A Walsh; M R Acevedo; S Hu; J Yao; C Wang; J J Sunderland; L L Boles Ponto
Journal:  Placenta       Date:  2014-12-23       Impact factor: 3.481

5.  Effect of insulin and dexamethasone on fetal assimilation of maternal glucose.

Authors:  Andrew W Norris; Chunlin Wang; Jianrong Yao; Susan A Walsh; Alexander B Sawatzke; Shanming Hu; John J Sunderland; Jeffrey L Segar; Laura L B Ponto
Journal:  Endocrinology       Date:  2010-11-17       Impact factor: 4.736

Review 6.  Use of Positron Emission Tomography for Pregnancy-Associated Cancer Assessment: A Review.

Authors:  Giulia Parpinel; Maria Elena Laudani; Francesca Paola Giunta; Chiara Germano; Paolo Zola; Bianca Masturzo
Journal:  J Clin Med       Date:  2022-07-01       Impact factor: 4.964

Review 7.  Radiation Absorbed Dose to the Embryo and Fetus from Radiopharmaceuticals.

Authors:  Paolo Zanotti-Fregonara
Journal:  Semin Nucl Med       Date:  2022-01-21       Impact factor: 4.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.